BACKGROUND AND PURPOSE: To examine the distributions of proton magnetic resonance spectroscopy (MRS) observed metabolites in Parkinson's disease (PD) throughout the whole brain. METHODS: Twelve PD patients and 18 age-matched controls were studied using neuropsychological testing, MRI and volumetric MR spectroscopic imaging. Average values of signal normalized metabolite values for N-acetyl-aspartate, total-creatine, and total-choline (NAA, total-Cre, total-Cho, respectively) and their ratios were calculated for gray matter (GM) and white matter (WM) in each lobar brain region. RESULTS: Analyses revealed altered metabolite values in PD subjects relative to controls within the GM of the temporal lobe (right: elevated Cre, P = .027; decreased NAA/Cre, P = .019; decreased Cho/Cre, P = .001 and left: decreased NAA/Cre; P = .001, decreased Cho/Cre, P = .007); the right occipital lobe (decreased NAA, P = .032 and NAA/Cre, P = .016); and the total cerebrum GM (decreased NAA/Cre, P = .029). No meaningful correlations were obtained between abnormal metabolite values and the neuropsychological measures. CONCLUSIONS: PD is associated with widespread alterations of brain metabolite concentrations, with a primary finding of increased creatine. Higher creatine values in our PD sample may reflect greater neuronal energy expenditure early in the disease process that is compensatory. This is the first whole brain MRS study of PD that has examined metabolite changes across a large fraction of the brain volume, including the cortical mantle.
BACKGROUND AND PURPOSE: To examine the distributions of proton magnetic resonance spectroscopy (MRS) observed metabolites in Parkinson's disease (PD) throughout the whole brain. METHODS: Twelve PDpatients and 18 age-matched controls were studied using neuropsychological testing, MRI and volumetric MR spectroscopic imaging. Average values of signal normalized metabolite values for N-acetyl-aspartate, total-creatine, and total-choline (NAA, total-Cre, total-Cho, respectively) and their ratios were calculated for gray matter (GM) and white matter (WM) in each lobar brain region. RESULTS: Analyses revealed altered metabolite values in PD subjects relative to controls within the GM of the temporal lobe (right: elevated Cre, P = .027; decreased NAA/Cre, P = .019; decreased Cho/Cre, P = .001 and left: decreased NAA/Cre; P = .001, decreased Cho/Cre, P = .007); the right occipital lobe (decreased NAA, P = .032 and NAA/Cre, P = .016); and the total cerebrum GM (decreased NAA/Cre, P = .029). No meaningful correlations were obtained between abnormal metabolite values and the neuropsychological measures. CONCLUSIONS:PD is associated with widespread alterations of brain metabolite concentrations, with a primary finding of increased creatine. Higher creatine values in our PD sample may reflect greater neuronal energy expenditure early in the disease process that is compensatory. This is the first whole brain MRS study of PD that has examined metabolite changes across a large fraction of the brain volume, including the cortical mantle.
Authors: A A Maudsley; A Darkazanli; J R Alger; L O Hall; N Schuff; C Studholme; Y Yu; A Ebel; A Frew; D Goldgof; Y Gu; R Pagare; F Rousseau; K Sivasankaran; B J Soher; P Weber; K Young; X Zhu Journal: NMR Biomed Date: 2006-06 Impact factor: 4.044
Authors: Richard Camicioli; M Milar Moore; Anthony Kinney; Elizabeth Corbridge; Kathryn Glassberg; Jeffrey A Kaye Journal: Mov Disord Date: 2003-07 Impact factor: 10.338
Authors: Joana B Pereira; Carme Junqué; Maria J Martí; Blanca Ramirez-Ruiz; David Bartrés-Faz; Eduard Tolosa Journal: Neuroreport Date: 2009-05-27 Impact factor: 1.837
Authors: M T Hu; S D Taylor-Robinson; K R Chaudhuri; J D Bell; C Labbé; V J Cunningham; M J Koepp; A Hammers; R G Morris; N Turjanski; D J Brooks Journal: Brain Date: 2000-02 Impact factor: 13.501
Authors: Eva Widerström-Noga; Varan Govind; James P Adcock; Bonnie E Levin; Andrew A Maudsley Journal: J Neurotrauma Date: 2016-01-15 Impact factor: 5.269
Authors: Mohammad Sabati; Sulaiman Sheriff; Meng Gu; Juan Wei; Henry Zhu; Peter B Barker; Daniel M Spielman; Jeffry R Alger; Andrew A Maudsley Journal: Magn Reson Med Date: 2014-10-29 Impact factor: 4.668
Authors: Benito de Celis Alonso; Silvia S Hidalgo-Tobón; Manuel Menéndez-González; José Salas-Pacheco; Oscar Arias-Carrión Journal: Front Neurol Date: 2015-07-03 Impact factor: 4.003